Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The study evaluates if a 6-month course of oral lovastatin at 80 mg/day would decrease
abnormal breast duct cytology in women with a high inherited breast cancer risk.